Cytomegalovirus-specific cytokine-induced killer cells: Concurrent targeting of leukemia and cytomegalovirus

Cytotherapy

Volumn 17, Issue 8, 2015, Pages 1139-1151

  Pfirrmann, Verena ^a   Oelsner, Sarah ^a,b   Rettinger, Eva ^a   Huenecke, Sabine ^a   Bonig, Halvard ^a   Merker, Michael ^a   Wels, Winfried S ^b   Cinatl, Jindrich ^a   Schubert, Ralf ^a   Klingebiel, Thomas ^a   Bader, Peter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

CIK cells; CMV; Cytotoxicity; Immunotherapy; Leukemia

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOIMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; CELL EXPANSION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOTOXICITY TEST; DEGRANULATION; FIBROBLAST; HUMAN; HUMAN CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; ADVERSE EFFECTS; BIOLOGICAL THERAPY; CYTOLOGY; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA; PATHOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION; TRANSPLANTATION; TUMOR CELL LINE; VIROLOGY;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

CELL LINE, TUMOR; CELL- AND TISSUE-BASED THERAPY; CYTOKINE-INDUCED KILLER CELLS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXICITY, IMMUNOLOGIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-15; INTERLEUKIN-2; LEUKEMIA; PHOSPHOPROTEINS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 84937639096     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.04.011     Document Type: Article

References (50)

1. Bader P., Kreyenberg H., Hoelle W., Dueckers G., Handgretinger R., Lang P., et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?. J Clin Oncol 2004, 22:1696-1705.
2. Bontant T., Sedlaçek P., Balduzzi A., Gaspar B., Cesaro S., Einsele H., et al. Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT. Bone Marrow Transplant 2014, 49:276-279.
3. Moore A.S., Kearns P.R., Knapper S., Pearson A.D., Zwaan C.M. Novel therapies for children with acute myeloid leukaemia. Leukemia 2013, 27:1451-1460.
4. Roboz G.J. Current treatment of acute myeloid leukemia. Curr Opin Oncol 2012, 24:711-719.
5. Gratwohl A., Brand R., Frassoni F., Rocha V., Niederwieser D., Reusser P., et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005, 36:757-769.
6. Reusser P., Riddell S.R., Meyers J.D., Greenberg P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
7. Bunos M, Hümmer C, Wingenfeld E, Sorg N, Pfirrmann V, Bader P, et al. Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise donor lymphocyte concentrates: results of a feasibility exercise [published online ahead of print May 7, 2015]. Vox Sanguinis.
8. Stemberger C., Graef P., Odendahl M., Albrecht J., Dössinger G., Anderl F., et al. Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 2014, 124:628-637.
9. Geyeregger R., Freimüller C., Stemberger J., Artwohl M., Witt V., Lion T., et al. First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation. J. Immunother 2014, 37:245-249.
10. Gerdemann U., Katari U.L., Papadopoulou A., Keirnan J.M., Craddock J.A., Liu H., et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013, 21:2113-2121.
11. Peggs K.S., Thomson K., Samuel E., Dyer G., Armoogum J., Chakraverty R., et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011, 52:49-57.
12. Hanley P.J., Cruz C.R., Savoldo B., Leen A.M., Stanojevic M., Khalil M., et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
13. Leen A.M., Myers G.D., Sili U., Huls M.H., Weiss H., Leung K.S., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-1166.
14. Blyth E., Clancy L., Simms R., Ma C.K., Burgess J., Deo S., et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013, 121:3745-3758.
15. Meij P., Jedema I., Zandvliet M.L., van der Heiden P.L., van de Meent M., van Egmond H.M., et al. Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines. J. Immunother 2012, 35:621-628.
16. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991, 174:139-149.
17. Lu P.H., Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153:1687-1696.
18. +T cells in healthy cytomegalovirus positive subjects. Immunology 2014, 142:258-268.
19. Kuçi S., Rettinger E., Voss B., Weber G., Stais M., Kreyenberg H., et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010, 95:1579-1586.
20. Sangiolo D., Martinuzzi E., Todorovic M., Vitaggio K., Vallario A., Jordaney N., et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008, 20:841-848.
21. Verneris M.R., Karami M., Baker J., Jayaswal A., Negrin R.S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004, 103:3065-3072.
22. Rettinger E., Kuçi S., Naumann I., Becker P., Kreyenberg H., Anzaghe M., et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2012, 14:91-103.
23. Della Chiesa M., Falco M., Bertaina A., Muccio L., Alicata C., Frassoni F., et al. Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/- umbilical cord blood. J Immunol 2014, 192:1471-1479.
24. Kuijpers T.W., Baars P.A., Dantin C., van den Burg M., van Lier R.A., Roosnek E. Human NK cells can control CMV infection in the absence of T cells. Blood 2008, 112:914-915.
25. Pievani A., Borleri G., Pende D., Moretta L., Rambaldi A., Golay J., et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310.
26. Michaelis M., Paulus C., Löschmann N., Dauth S., Stange E., Doerr H.W., et al. The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell Mol Life Sci 2011, 68:1079-1090.
27. Rettinger E., Kreyenberg H., Merker M., Kuçi S., Willasch A., Bug G., et al. Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion. Cytotherapy 2014, 16:835-844.
28. Bonnekoh B., Wevers A., Jugert F., Merk H., Mahrle G. Colorimetric growth assay for epidermal cell cultures by their crystal violet binding capacity. Arch Dermatol Res 1989, 281:487-490.
29. Sellar R.S., Peggs K.S. The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation. Cytotherapy 2012, 14:391-400.
30. Uhlin M., Gertow J., Uzunel M., Okas M., Berglund S., Watz E., et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012, 55:1064-1073.
31. Feuchtinger T., Opherk K., Bethge W.A., Topp M.S., Schuster F.R., Weissinger E.M., et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367.
32. Hensel N., Melenhorst J.J., Bradstock K., Schwarer A.P., Eniafe R., Nakamura R., et al. Flow cytometric quantitation and characterization of the T-lymphocyte memory response to CMV in healthy donors. Cytotherapy 2002, 4:29-40.
33. Linn Y.C., Lau S.K., Liu B.H., Ng L.H., Yong H.X., Hui K.M. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2009, 126:423-435.
34. Sangiolo D., Mesiano G., Carnevale-Schianca F., Piacibello W., Aglietta M., Cignetti A. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther 2009, 9:831-840.
35. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., Fernandez L.P., Huhn D., Blume K.G., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993, 21:1673-1679.
36. Ortaldo J.R., Winkler-Pickett R.T., Yagita H., Young H.A. Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 1991, 136:486-495.
37. Lin S., Cheng P., Yan D., Lee P., Hsaio H. Effect of interleukin-15 on alloreactivity in umbilical cord blood. Transpl Immunol 2006, 16:112-116.
38. Blaser B.W., Roychowdhury S., Kim D.J., Schwind N.R., Bhatt D., Yuan W., et al. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood 2005, 105:894-901.
39. Linn Y., Yong H., Niam M., Lim T., Chu S., Choong A., et al. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy 2012, 14:851-859.
40. Laport G.G., Sheehan K., Baker J., Armstrong R., Wong R.M., Lowsky R., et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant 2011, 17:1679-1687.
41. Introna M., Borleri G., Conti E., Franceschetti M., Barbui A.M., Broady R., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952-959.
42. Rettinger E., Bonig H., Wehner S., Lucchini G., Willasch A., Jarisch A., et al. Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. Bone Marrow Transplant 2013, 48:1141-1143.
43. Scheper W., van Dorp S., Kersting S., Pietersma F., Lindemans C., Hol S., et al. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013, 27:1328-1338.
44. Franceschetti M., Pievani A., Borleri G., Vago L., Fleischhauer K., Golay J., et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009, 37:616-628.e2.
45. Lugli E., Dominguez M.H., Gattinoni L., Chattopadhyay P.K., Bolton D.L., Song K., et al. Superior T memory stem cell persistence supports long-lived T cell memory. J. Clin. Invest 2013, 123:594-599.
46. Joshi N.S., Cui W., Chandele A., Lee H.K., Urso D.R., Hagman J., et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007, 27:281-295.
47. Sabbagh L., Kaech S.M., Bourbonniere M., Woo M., Cohen L.Y., Haddad E.K., et al. The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol 2004, 173:5425-5433.
48. Cua D.J., Tato C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010, 10:479-489.
49. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu Rev Immunol 1997, 15:749-795.
50. Nishimura R., Baker J., Beilhack A., Zeiser R., Olson J.A., Sega E.I., et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008, 112:2563-2574.